HLA-A and cutaneous melanoma: The Phase III study conducted by Schwartzentruber et al., investigated the clinical response and toxicity of the gp100:209–217 (210M) peptide vaccine with Montanide ISA-51 adjuvant +/− Interleukin-2 (IL-2) with HLA-A*02:01 patients with stage IV or locally advanced stage III cutaneous melanoma [34].